YIH
CADL icon

Y-Intercept (HK)’s Candel Therapeutics CADL Stock Holding History

Y-Intercept (HK)’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$705K Buy
+68,472
New +$517K 0.01% 1191

Other funds holding CADL

CSP
Cary Street Partners Richmond, Virginia $4.58B AUM 24% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
LF
LifeSteps Financial Claremont, California $215M AUM 27.52% 1-Year Est. Return

Y-Intercept (HK)'s CADL Position: Q2 2026 in Review

Y-Intercept (HK) opened a new position in Candel Therapeutics (CADL) in Q2 2026: 68,472 shares worth $705K. The stake represents 0.01% of the portfolio and ranks #1191 among its holdings.

6 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

  • Y-Intercept (HK) held 68,472 shares of Candel Therapeutics worth $705K as of Q2 2026.
  • Candel Therapeutics was a new Y-Intercept (HK) position in Q2 2026.
  • Candel Therapeutics made up 0.01% of Y-Intercept (HK)'s portfolio in Q2 2026, its #1191 holding.
  • 6 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on Y-Intercept (HK)'s 13F filing for Q2 2026, filed 14 Jul 2026.